According to Frost & Sullivan Frost & Sullivan According to the forecast of 'Frost & Sullivan' (hereinafter referred to as 'Frost & Sullivan'), by 2030 In [year], the global market size of self-administered immunotherapy drugs is expected to reach 1,760 billion US dollars 2022-2030 Annual Compound Annual Growth Rate 3.6% Among them, the market scale of China's self-administered drugs 2030 The year is expected to reach nearly 250 billion US dollars, compared to 2020 Achieving a tenfold growth in annual revenue is an important source of incremental demand for global autoimmune drugs. The autoimmune drug market is the second-largest pharmaceutical market globally after oncology, but it has already entered a highly competitive phase compared to the oncology market. The autoimmune drug market still needs further development. What are the reasons why the domestic autoimmune market space was not yet opened up? What are the driving factors behind the rapid development of the domestic autoimmune market in the past two years?     Hao Shuai, Senior Consulting Manager at Frost & Sullivan's Life Sciences Practice in Greater China, was interviewed by 'Securities Daily' to discuss the current development status of the market for self-administered drugs.   Securities Daily   * Click at the end of the article Read the original text View the full report       Q :    The autoimmune drug market is the second largest pharmaceutical market globally, after oncology. However, compared to the highly competitive oncology market, the autoimmune drug market still needs further development. What are the reasons why the domestic autoimmune market space has not yet opened up? a) Insufficient market education: The education and promotion of the self-administered drug market in China are relatively insufficient. Many patients and doctors have limited knowledge and understanding of self-administered drugs, which limits further market expansion. b) Medical insurance restrictions: Since self-administered drugs are usually more expensive, and China's medical insurance policy mainly supports drug types that have been on the market for a longer time and are clinically mature, this has led to some self-administered drugs, especially innovative ones, not being covered by medical insurance, limiting patients' choices. c) Patient affordability: The price of self-immune drugs is relatively high, making it difficult for many patients to afford the cost of self-funded treatment. Therefore, the clinical demand for self-immune drugs is limited. In addition, since autoimmune diseases are usually not fatal, Chinese patients are mostly reluctant to invest a large amount of economic resources in treating diseases like cancer when they have limited financial capabilities and are sensitive to prices. As a result, this leads to interruptions in treatment and ineffective treatment for patients. d) Supervision and Approval: The R&D and marketing approval process for self-medicating drugs, especially innovative ones, is lengthy, involving strict clinical trials and regulatory approvals. This increases the cost and cycle of drug development and has also led to a slowdown in drug market launch speed.     Q :    Some pharmaceutical companies pointed out, 2023 In the year, the field of autoimmune diseases entered a period of rapid development. 2024 The year is expected to become the commercialization year for domestic self-administered immunotherapy products. What are the driving factors behind the rapid development of the domestic self-administered immunotherapy market in the past two years? a) The sales of blockbuster drugs in the self-immune space are accelerating: Many blockbuster drugs developed by multinational companies have been approved in China and included in the national medical insurance; sales have increased while unit prices have decreased. For example, siltuximab 2019 year 3 In China, monthly has been approved for the treatment of moderate to severe plaque psoriasis, and 2021 year 3 Included in the national medical insurance monthly. Its domestic sales since 2020 year 72.5 Millions of dollars rose to 2021 year 279.0 One million US dollars and 2022 year 601.4 One million US dollars. In addition, dupilumab is available in 2020 year 6 Approved in November for the treatment of moderate to severe atopic dermatitis, and 2021 year 1 Included in the national medical insurance monthly. Its domestic sales since 2020 year 13.7 Millions of dollars rose to 2021 year 87.4 One million US dollars and 2022 year 248.1 One million US dollars. The rapid growth in sales of blockbuster drugs in the autoimmune field in China will continue to drive China into the first year of commercialization in the autoimmune disease space. b) Technological innovation and treatment plan upgrades: Technological innovation in the field of self-immune drugs has continuously driven the development of new drugs, making treatment options for autoimmune diseases more diverse. As treatment plans for autoimmune diseases gradually shift from traditional anti-inflammatory drugs to biologics, the category of biologic drugs has also been continuously upgraded. For example, compared with the first-generation drugs that carry a higher risk of severe infections TNF- Alpha-blockers, targeting interleukins (for example IL-17 and IL-23 Several types of biological agents have shown better efficacy in certain indications, such as / Or safety, as biopharmaceutical manufacturers continue to advance extensive pre-marketing studies. In the future, more self-administered immunotherapy drugs will be approved in China, driving market scale growth. c) Increased clinical demand: With the aging population and changes in lifestyle, the number of patients with autoimmune diseases is increasing year by year, and the treatment needs of patients are constantly rising. Autoimmune diseases are typical chronic conditions that require long-term or even lifelong medication. Patients have a stable long-term demand for drugs, hence the high clinical demand for autoimmune drugs and the huge potential of the drug market. d) Policy Support: The Chinese government has been increasing its support for the pharmaceutical industry, including accelerating approval processes and simplifying registration procedures, providing favorable conditions for the research and development and market launch of self-administered drugs, and promoting the accelerated growth of China's self-administered drug market. e) Market Opportunities and the Rise of Chinese Local Enterprises: The market for autoimmune diseases is huge, and compared to the crowded field of oncology where international and local pharmaceutical companies compete fiercely, the market competition is relatively less intense, providing development opportunities for new entrants. After recognizing the tremendous potential in this therapeutic area, Chinese local innovative pharmaceutical companies have begun continuous research and development on autoimmune disease drugs. Autoimmune drugs developed by local innovative pharmaceutical companies will have a greater pricing advantage, and domestic companies can make more use of their in-depth understanding and extensive coverage of local patients and hospitals to propose more targeted market promotion strategies alongside multinational companies, improving patients' educational level and enhancing their awareness of autoimmune diseases and drug treatment.   * This interview has been published in 'Securities Daily', with reporter Sun Wenqing, and the original title was:    JugEM's autoimmune disease drug market The enthusiasm of domestic pharmaceutical companies for research and development has been reignited    ">

6 month 3 Today, Youbo Holdings is listed on the Hong Kong Stock Exchange GEM index Listing. This is the first time since the Hong Kong Growth Enterprise Market started 2021 year 1 month 13 The first new stock since yesterday. Youbo Holdings has become GEM index What is the demonstration significance of the first company to successfully go public in three years? What are the highlights after the reform of the Hong Kong Growth Enterprise Market? In which aspects is it attractive to companies applying for listing in the future? Which industries are expected? / Benefiting enterprises of a certain type?     Frost & Sullivan Frost & Sullivan, Frost & Sullivan, referred to below as 'Frost & Sullivan', provides exclusive industry advisory services for the listing of Youbo Holdings. Xiang Weili, Executive Director of Frost & Sullivan Greater China, was interviewed by Securities Daily to discuss the Hong Kong Stock Exchange GEM index Current situation.   Securities Daily   * Click at the end of the article Read the original text View the full report       Q :    UBEC Holdings became GEM index What is the demonstrative significance of the first company to successfully go public in three years?   since 2018 Since the reform a year ago, GEM index The number of listings and financing amounts have declined for various reasons. 2023 year 9 month GEM index We launched a secondary reform, reintroduced the simplified transfer board mechanism, and are committed to meeting the financing needs of more small and medium-sized enterprises. 2024 shall come into force on [date]. Yubo Holdings hereby GEM index The successful listing proves that GEM index The feasibility and effectiveness of the reform have boosted the confidence of enterprises and investors, which will encourage more high-quality enterprises to list in Hong Kong for financing, ultimately enhancing the overall Hong Kong stock market. IPO listing The international influence of the market.     Q :    What are the highlights of the Hong Kong Growth Enterprise Market (GEM) reform? In what aspects does it attract subsequent companies applying for listing? Which industries are expected to be affected? / Benefiting enterprises of a certain type? GEM index The reform introduces a simplified transfer mechanism, such as allowing issuers to apply to transfer to the main board without appointing a sponsor for due diligence or publishing listing documents that meet the 'Prospectus Standard', GEM index The post-listing embargo period for the controlling shareholder of the issuer is from 24 months are shortened to 12 months, removing the requirement for mandatory quarterly performance reports, etc., provide more convenient and transparent pathways for subsequent applicants to transfer to the main board for listing, reducing compliance costs for listing and attracting high-quality enterprises interested in listing to apply earlier. It is expected that this reform will help more enterprises like mainland companies and technology-based small and medium-sized enterprises with high development potential GEM index Going public has helped them thrive.   * This interview has been published in 'Securities Daily', with reporter Mao Yirong, and the original title was:    More than three years later, Hong Kong stocks and ChiNext welcome new listings Everbright Holdings rose on its listing day 6%    ">     Recommended Reading         🔗 Good News on Listing | Frost & Sullivan Assists UBO Holdings Limited in Successful Hong Kong Listing (8529.HK)

Kerryang Red Bean and Coix Seed Water Innovation Leadership Program Launch Conference 5 month 30 Date, hosted by Shandong Keyang Beverage Co., Ltd. 2024 The Chinese Light Health Beverage Development Forum and the Keryang Red Bean Coix Seed Water Innovation Leadership Plan Launch Event was successfully held in Beijing. The forum, themed 'National Light Health Preservation', aimed to explore the genes behind health beverage breakthrough products of the new era.   Frost & Sullivan Frost & Sullivan Cai Jinfeng, Executive Director of Frost & Sullivan's Greater China Region, was invited to attend the event and provided an in-depth interpretation of the 'China Light Living Consumption Report' (hereinafter referred to as the 'Report') at the press conference. Executive Director, Greater China, Frost & Sullivan Cai Jinfeng Cai Jinfeng pointed out that in recent years, the rapid development of the Chinese economy has driven up residents' living standards. However, the increased calorie intake in daily diets has led to an increase in obesity rates, and the number of people suffering from complications such as diabetes and fatty liver has also been continuously rising. At the same time, with the acceleration of the modern pace of life and the prevalence of fast food culture, many young people have irregular and unhealthy eating habits. In addition, as population aging intensifies, the base number of chronic disease patients continues to grow, and the elderly's demand for healthy living is particularly urgent. As of 2023 In 1.4 Hundreds of millions of diabetic patients, 2.8 100 million fatty liver patients 2.3 Number of obese people and overweight individuals 1/3 The population has a problem with overweight, compared 5 Several sets of data improved significantly before the New Year. Faced with increasingly severe sub-health issues, people's demand for a lighter lifestyle has grown stronger, and the widespread sub-health problems have also drawn attention and awakened awareness in recent years. According to data from the National Health Commission, in recent years, the health literacy level of Chinese residents has been continuously improving. Among them, residents have the deepest understanding of basic knowledge and concepts, and have made the greatest progress in improving their healthy lifestyles and behaviors. This is also attributed to the pandemic which has enhanced residents' awareness of health and encouraged them to actively improve their original lifestyles. The comprehensive improvement in national health awareness has also laid a solid foundation for the light lifestyle industry.   According to Frost & Sullivan research, the comprehensive improvement in national health awareness is reflected in people's deeper and more multi-dimensional attention to their daily living conditions. For example, emotional issues, nutritional status, skin, oral health, weight, and so on—these increasingly diversified health and wellness needs are actively driving the development of the light lifestyle industry. 'Previously, industries such as clothing, food, housing, and transportation that were part of our daily lives were also actively embracing light lifestyles, expanding the dimensions of overall industry development, and continuously producing convenient, fast, and diverse light lifestyle products and services for consumers,' said Cai Jinfeng. According to Cai Jinfeng, light lifestyle originates from traditional health preservation concepts. Compared to traditional health preservation, it encompasses a broader range and is more lightweight and convenient in form. Traditional health preservation often involves traditional Chinese medicine, herbal medicines, or nourishing products, emphasizing the maintenance of health through conditioning methods. In contrast, light lifestyle is more adaptable to modern fast-paced life, helping people maintain and improve their health levels through more lightweight and flexible health preservation methods in daily life. It covers multiple fields such as food, beverages, home appliances, fitness, electronic products, culture and tourism, meeting the diverse and multi-scenario health preservation needs of different groups of people. Among them, healthy beverages and healthy foods are two highly representative types that have also been favored by consumers in recent years. The core product elements of these two major fields also reflect the current most frequent health preservation concerns of consumers, such as low calories, natural ingredients, and affordability. When discussing a light lifestyle, the development and industrial iteration and upgrading of the health product industry are also closely related. Cai Jinfeng further added that looking back at the past few decades, China's health food industry has gone through four important stages. Consumer awareness and cognition have gradually improved with market development, and product forms and distribution channels have become increasingly diverse. In the budding stage, mainly nourishing products were dominant, domestic enterprises developed in an unregulated manner, lacking supervision, and the market was chaotic; during the growth stage, mature overseas brands entered China one after another, and citizens began to come into contact with more advanced health concepts; in the standardization stage, a large number of overseas health products flooded into the Chinese market, and relevant policies and regulations were issued during this period to standardize the high-quality development of the industry; 2020 Since the beginning of this year, China's health product industry has also entered a period of rapid development. The industrial chain has gradually matured, and product forms and distribution channels have become increasingly diverse. At the same time, consumers' understanding of healthy foods has further improved, making healthy foods gradually mainstream today. Relying on China's strong supply chain capabilities, the light wellness industry chain is becoming increasingly mature and complete. In the field of light wellness lifestyle, many leading enterprises such as Keryan, Yuanqi Forest, Little Fairy Stew, Belief, and Juzi Biology have emerged, pioneering new territories and providing escort for the nation to embrace a healthy light wellness lifestyle. Cai Jinfeng stated that China's light wellness industry is moving towards a development path of standardization, scale-up, vertical integration, and branding. According to Frost & Sullivan research, driven by favorable government policies, enhanced national health awareness, diversified retail channels, and increased consumer purchasing, the market size of health food in China has now exceeded 6,000 billion, and it is expected to be 2028 The year will break through 8,000 The billion mark is a crucial threshold, and the future trillion-dollar market is just around the corner. Cai Jinfeng pointed out that after going through the 'sugar substitute era' to the 'true zero-sugar era', the public's understanding of the concept of 'sugar-free' has been greatly enhanced, and 'sugar-free' products have also received the preference and widespread acceptance of consumers. According to Frost & Sullivan research, the market size of zero-sugar beverages in China has currently exceeded 250 billion, and it is expected to be 2028 The year will break through 500 At the 100-billion mark, emerging brands will continue to emerge in the vertical segments of sugar-free beverages. The market is poised for rapid development in the future. The vigorous development of the light cultivation lifestyle industry cannot be separated from government guidance and support. 2016 Since the beginning of this year, the Chinese government has successively issued a series of guidelines to stimulate enterprise vitality and improve the health literacy of the entire population, providing a solid guarantee for the scale-up and specialization development of the industry. At the supply side, enterprises are accelerating their response to consumer pain points and demands through product innovation, technological upgrading, and resource integration. In recent years, with the improvement of people's health awareness and their pursuit of quality life, consumers have also developed new demands for healthy diets, and 'food as medicine' has become a breakthrough point in healthy eating. As a representative of 'food and medicine in one' health beverages, red bean and coix seed drinks have ignited the market in recent years, gradually infiltrating consumers' daily lives from the realm of health preservation and becoming a popular health beverage. Although technology is iterating, the heritage remains unchanged. From red bean and coix seed tea to bottled red bean and coix seed water, what has been passed down is the essence of China's ancient dietary culture over thousands of years, while what has changed is the new way people pursue a healthy lifestyle. The launch of Yoyang bottled coix seed water represents an important transformation for both the industry and national health diets.   Based on insights into the Chinese health beverage market and cross-validated with primary research and desk research data, as an internationally authoritative consulting firm, Frost & Sullivan has awarded Keyang the market position confirmation certificates of 'Pioneer of Bottled Red Bean and Coix Seed Water' and 'No.1 Saleser of Bottled Red Bean and Coix Seed Water Nationwide'. At this forum, Cai Jinfeng presented a market standing confirmation certificate to Keyang. Cai Jinfeng presented the Market Standing Confirmation Certificate to Keyang

CBE International Cosmetics Technology Conference China's gravity leads beauty tech, 5 month 21 day, 2024CBE The International Cosmetics Technology Conference and the Asia-Pacific Science and Technology Exchange Summit successfully concluded at the Kerry Hotel in Pudong, Shanghai. The 9th session CBE The International Cosmetics Technology Conference, themed 'China's Gravity', starts from two major sections: 'International Forward-looking Trends' and 'China's Scientific Research Gravity'. It focuses on emerging science and technology, brand R&D system construction, and effective scientific communication pathways. It aggregates the emerging energy of the industry, seeks new benchmarks, responds to the national strategy of leading the construction of a modern beautiful and healthy industry system with technological innovation and developing new productive forces, and jointly explores new engines for technological innovation with Chinese and foreign industry experts.   Frost & Sullivan Frost & Sullivan Li Qian, the consulting director of Frost & Sullivan's Life Sciences business unit in Greater China, was invited to attend the event and delivered a keynote speech titled 'The New Era of 'Beauty Economy': Industrial Chain Mapping and New Technological Trends'. Deputy Director of Shanghai Drug Administration Zhao Yanjun   Zhao Yanjun, Deputy Director of the Shanghai Municipal Drug Administration, delivered a wonderful opening speech for the conference.   She stated, 'As the Chinese cosmetics industry develops rapidly, China's cosmetics regulatory system has entered a new era of 'institutionalized, legalized, and standardized management of cosmetics'. It is hoped that the representatives from the cosmetics industry present can actively advocate for cosmetics companies to implement their main responsibility for quality and safety, work together to escort the upgrading of the beauty industry, and enable more new technologies, tools, methods, and products to serve the growing needs of people for a better life, thereby stimulating the entire industry to think about and explore new productive forces.' Consulting Director, Life Sciences Business Unit, Frost & Sullivan Greater China Region Li Qian Li Qian pointed out that the 'beauty economy' has penetrated into every aspect of daily life, giving rise to a vast field that encompasses multiple industries such as cosmetics, skincare products, medical aesthetics, fashion clothing, fitness and body shaping, beauty photography, and online beauty communities. Innovative technology plays an important role in the development of the 'beauty economy'. Taking the beauty and medical aesthetics product industry as an example, a relatively complete industrial chain from upstream to downstream has now been formed. Various production factors collaborate within the industrial chain, actively promoting industry development.   According to Frost & Sullivan research, driven by both demand and supply sides, the market scale of medical aesthetics in China is expanding rapidly, with an estimated 2025 In [year], the market scale of non-surgical medical beauty services in China will reach 2,046 1000 million RMB. When discussing the development trend of the 'beauty economy', Li Qian said, 'Firstly, the development of new technologies provides new ideas for 'becoming beautiful', such as synthetic biology breaking through production limits and reducing production costs; precision medicine offering customized 'beauty' solutions; secondly, the iterative upgrading of traditional materials and the development of new materials continuously break through demand boundaries, providing consumers with more choices; finally, the promotion of new concepts prompts consumers to update their 'beauty' concepts, which will further drive the development of the 'beauty economy'.'   More exciting moments from the event arena Recommended Reading About Frost & Sullivan's Life Sciences Practice The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life science industry. The Life Sciences Practice has a wide range of corporate clients in China and in the past 20 In the year, a vast customer network was established, accumulating extensive project experience in various subfields of life sciences. Project types include Knowledge Center projects (in-depth content and promotional activities). Pre-IPO financing project DCF model Valuation, Business Plan Services), IPO listing We provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized sub-sectors such as pharmaceuticals and medical devices, attracting widespread attention from investors.  

On May 26th, the finals of the Second National College Students' Industry Forecasting Competition were successfully held at the Baidu PaddlePaddle AI Industry Empowerment Center. The event was co-hosted by Frost & Sullivan (abbreviated as 'Frost & Sullivan'), Gaodun Education, and LeadLeo, with the assistance of Baidu Wenxin Yiyan, aiming to provide college students with the highest quality competition content and jointly create a financial competition platform integrating competition and training.   The competition lasted for 2 months and covered 751 universities and more than 2,100 seed teams. After going through stages such as preliminary rounds and semi-finals, 10 elite teams from around the world gathered together. Through carefully prepared group roadshows, they demonstrated their unique insights and in-depth analysis into future industry development. Each team won high recognition from the audience and judges with their unique creativity and solid professional knowledge. Guest Speech Wang Chenhui, Managing Partner and President of Frost & Sullivan Greater China, and Co-founder and President of LeadLeo, emphasized that the original intention of the competition is to transform industry research into a core competitiveness for students, enabling them to develop comprehensively like hexagonal warriors and stand out in the face of any challenge. He pointed out that the competition integrates more AI technology through a rapid iterative system and format, aiming to accelerate the learning process, promote the sharing and innovation of knowledge and experience, and provide a new platform for young researchers to enhance their capabilities. Wang Chenhui, Partner-in-Chief and President of Frost & Sullivan Greater China Region, Co-founder and President of LeadLeo   Zhang Tao, General Manager of the Finance Department at Gaodun Education for College Students, fully agrees with this view. He believes that the competition is not only an exercise in hard skills such as report writing, model prediction, and business writing, but also a cultivation of soft skills such as logical thinking, business acumen, and public speaking abilities. Zhang Tao emphasizes that this platform provides valuable practical opportunities for participants, helping them grow in the fierce competition while also gaining precious friendships and valuable life experiences. Zhang Tao, General Manager of the Finance Department at GaoDun Education for College Students   Cao Neng, Director of the Career Development Center at Fudan University School of Management, starts from the perspective of career development and proposes that in today's increasingly advanced AI technology era, a person's core competitiveness lies in self-awareness and continuous passion. Director Cao encourages students to first discover and cultivate their interests, transform them into professional skills, and ultimately continuously expand their boundaries in their long-term careers. He firmly believes that AI technology will make everyone a 'super individual', providing a broader space for learning and development. He hopes that everyone can learn from even failures and achieve growth. Cao Neng, Director of the Career Development Center at Fudan University School of Management   Introduction to the Jury and Project Roadshow The judging panel for this finals consists of several senior professionals, including Zhang Jian, Partner and Managing Director of Frost & Sullivan Greater China, Han Xiaochen, Executive General Manager of Zhongtai Securities, Zhang Xinyan, Founder and CEO of HuiPerData, Zhang Xuejiang, Director of the Manufacturing Management Project at NIO, Zou Zhenjie, a reporter/editor at CBN (China Business News), and Fu Yunchuan, Research Director of the Asset Management Department at Western Securities.   In the final, a project roadshow session is conducted, followed by scoring by professional judges. The highest and lowest scores are removed, and the average score is taken as the group's final score. Teams are ranked based on their final scores to determine the ultimate winner. Zhang Jian, Partner and Managing Director of Frost & Sullivan Greater China   Fu Yunchuan, Research Director of Asset Management Department, Western Securities   Han Xiaochen, Executive General Manager of Zhongtai Securities   Founder and CEO of Huiyue Digital, Zhang Xinyan   Zhang Xuejiang, Director of Manufacturing Management Project at NIO   Zou Zhenjie, Reporter/Editor of CBN (Cultural and Media Group), 1QFN   Subsequently, 10 participating teams made their appearances one after another, showcasing their talents and engaging in a fierce roadshow competition. Multiple detailed and rigorous research reports and creative research projects demonstrated the participating teams' spirit of continuous breakthroughs and innovation under the professional guidance of the competition team's research professionals.   After the competition, the judges expressed their opinions freely and provided professional guidance and rigorous evaluation of the roadshow projects. They offered important references and improvement suggestions to the participating teams. In the end, Wang Chenhui and Zou Zhenjie, on behalf of the judging panel, summarized and commented on the performance of all participating teams. Wang Chenhui made a summary and comments   Zou Zhenjie made a summary and comments   Announcement of Results and Awards Based on the comprehensive scoring and the collective decision of the judges, the final scores of the 10 participating teams were officially announced. At the end of the event, Zhang Jian, Cao Neng, Han Xiaochen, Zhang Xuejiang, and Fu Yunchuan presented the awards for champion, runner-up, third place, 'Most Innovative', and 'Best Popularity' to the winning teams respectively. Zhang Jian presented the award to the champion team (Sun Yat-sen University's "Prophets' Team")   Cao En presented the award to the runner-up team (Central South University of Economics and Law, Nanchang Hangkong University, Fuzhou University, Sichuan University 'Xiamen No.1 Middle School's amazing team').   Han Xiaochen presented the award to the third-place team (Yunnan University of Finance and Economics 'Invincible Team').   Zhang Xuejiang presented awards to the most innovative team (Shenzhen University's 'Wenshan Lake Team').   Fu Yunchuan presented the award to the Most Popular Team (Guangdong University of Technology's 'Technology + Subjective Initiative Team').   As a research competition targeting college students nationwide, this event not only provides a platform for participants to showcase their talents but also offers them an opportunity to exchange ideas and learn from industry experts and peers. Through the competition, participants have not only honed their analytical skills and teamwork abilities but also deepened their understanding of future industry development trends.   With the successful conclusion of this competition, we believe that in the future, more college students will join this industry full of challenges and opportunities, jointly driving the development and progress of the industry. We also sincerely look forward to the next competition, which will continue to provide a stage for more young people with dreams and talents to showcase their abilities.

Foodaily FBIC2024   Over the past year, the food and beverage industry has undergone tremendous changes both internally and externally.    The global trade pattern is being reshaped, and the domestic retail business environment is undergoing significant changes. A new zero-sum supply chain relationship with Chinese characteristics is about to take shape, making consumption grading more apparent. Driven by factors such as technology and the internet, global information flows, supply chains, and channels are presenting themselves in a flattened manner to every stakeholder, with spatial boundaries gradually narrowing or even being broken.   In the new era of food, the food and beverage industry structure has become more complex, and the competitive landscape is becoming increasingly unpredictable. What challenges will changes in consumer demand, significant channel transformations, industrial digitization, and global market development bring to the industry ecosystem? How should brands adapt to these changes to achieve steady development or even break through growth constraints?   Recently, Foodaily Daily Food Hosted Foodaily FBIC2024 Global Food & Beverage Innovation Conference (with Foodaily The China International Industry Fair (held during the same period) was held at the Shanghai National Convention and Exhibition Center. With the theme of "Breaking Through the Industrial Chain and Creating a New Situation Together", this conference gathered 150+ Business leaders and industry bigwigs, 4000+ Brand and product decision-makers, through all summit sessions, categories & The thematic forum and multiple segments such as Global Innovation Tasting examine the inspiration, opportunities, and implementation solutions for local innovation development from a global perspective. Together, they explore the core value of the industrial chain ecosystem to help brands achieve market segmentation and sustained stable growth.   The summit invited representatives of outstanding enterprises in the industry and influential industry leaders to discuss hot topics such as retail transformation, digital and intelligent innovation, scenario-driven trends, and domestic brands going global. Together, they explored new solutions for domestic food and beverage brands to innovate and break through barriers.   Frost & Sullivan Frost & Sullivan Zhang Jian, Partner and Managing Director of Frost & Sullivan's Greater China Region, was invited to attend the event as the moderator of the roundtable forum. He will be joined by Su Qiang, Vice President of General Mills International Business Unit, President and Managing Director of China Region; Wang Bing, Co-founder and Chairman of October Ricefield; and Tao Shiquan, Founder of Jiangxiaobai. Chairman Wang Zhengqi of Mo Xiaoxian, together with others, discussed 'Breaking Through the Industrial Chain and How to Co-create a New Situation'. Partner and Managing Director of Frost & Sullivan Greater China Region Zhang Jian After experiencing a period of rapid growth followed by a cooling-down phase, how should new consumer brands return to the core value of the industrial chain ecosystem and achieve a breakthrough?   Zhang Jian, Partner and Managing Director of Frost & Sullivan Greater China, said:   "Firstly, brands should re-examine their mission and vision, establish a connection with consumers' minds, and provide corresponding high-quality products and services based on customer needs. Secondly, new consumer brands also need to focus on innovation and differentiated competition, continuously improve product performance and user experience, and shape a unique brand image. In addition, strengthen cooperation with supply chain partners to ensure the quality and stability of raw materials. At the same time, in terms of marketing and communication, brands can create unique brand stories through content creation, social media marketing, etc., to attract consumer attention and build brand loyalty. The above measures will help new consumer brands stand out in the highly competitive market, achieve sustainable development, and break through the market."   Su Qiang, Vice President of GMF International Business Unit, President and Managing Director of China Region, said:   "The Chinese market presents huge opportunities for population segmentation and product differentiation, which is a unique advantage for new consumer brands. In the face of these opportunities, it is essential to deeply understand consumers' pain points and needs. Whether it's cost-effectiveness, quality-price ratio, or convenience, all should be connected with consumers on an emotional level. However, the most important thing in food production is to maintain the bottom line of food safety and quality. General Mills believes that ' Create food that the world loves ' Our purpose is to follow the value of continuous innovation in growth. Among these, we place special emphasis on cost management across the entire value chain. While maintaining our core competitiveness in high-quality raw materials and ingredients, we focus on the consumer as the center. By eliminating low-value-added activities in our overall operations, we can offer products with high cost-effectiveness in today's market environment.   Tao Shiquan, founder of Jiangxiaobai, said:   "The essence of consumer goods is three things—delivering products, being user-centered, and connecting products with users. Other aspects such as branding, operations, organization, and channels only connect these two elements; the key lies in shortening or making the chain between products and users more efficient. If consumer goods companies do not have sufficient capabilities at the source end or do not shorten the chain between production and consumption to improve efficiency, they will find it difficult to stand firm in the market. At the beginning of development, companies should have a long-term vision centered on the end goal, be brave in imagination, otherwise they are likely to cram at the last minute and only solve immediate problems. I hope everyone can face the future with unparalleled confidence and determination, regardless of how other industries develop, the food and beverage industry will always accompany the entire lifecycle of humanity. As long as we can create better and more distinctive products than others, we can embrace the future."   Wang Bing, co-founder and chairman of October Rice Field, said:    "   We are 2010 We started working on the 'October Rice Field' brand in the year following its launch, as agricultural products need to be branded for added value. Our products are difficult to find in supermarkets, so we seized the opportunity of the internet to deeply cultivate and operate online channels. 2016 In [year], we caught up with the trend of consumption upgrading and internet channel transformation in China, building a brand image for the rice category in the hearts of consumers. The previous marketing efforts greatly fed back into the production of the supply chain. I believe that to break through the industrial chain, we need to emphasize branding and omni-channel marketing. Relying on brand building can achieve breakthroughs and connectivity across the entire chain. Today's fast-moving consumer goods companies find it difficult; they need to build channel capabilities, informatization, and organizational capacity. Informatization indeed brings both opportunities and challenges, as well as huge growth potential. From standing out to achieving today's results, October Rice Field has benefited from its deep cultivation and continuous penetration of all channels.   Chairman Wang Zhengqi of Moxiao Xian said:    "   Many industries have monopolized their distribution channels, necessitating new channel reforms to give rise to new brands. However, the product lifecycle of new channels is often very short. How to take advantage of channel reform opportunities and how to understand consumer demand are challenging aspects for the development of emerging brands. The ability to produce products is not just about supply chain issues but also requires an organized management system that oversees all aspects. It is difficult for a new brand without scale to build a supply chain, and whether to establish one after gaining scale is another tough choice. Since the lifecycle of internet products is relatively short, it may be that once the supply chain is established, the product becomes unsellable. Although small businesses face difficulties, they also have development opportunities. Many large enterprises are reluctant to engage in too detailed business operations, suffering from severe internal strife and difficulty balancing short-term and long-term interests. These large enterprises' problems and dilemmas in seizing the market are actually opportunities for small brands. Small brands can seize opportunities in diverse distribution channels. Recommended Reading Recent Cases of Market Positioning Confirmation in the Catering and Retail, Food & Beverage Sectors (Scroll Up and Down for More) The Hunan cuisine market is booming, with branding and chain operations continuing to lead the future Safe and delicious, satisfying the public's taste buds, hot pot butter empowers quality upgrades for catering businesses Driven by the increasing demand for healthy and diverse diets and the leadership of leading enterprises, China's small poultry market has entered a new era of development China's wonton dumpling industry: Empowered by healthy nutrition, innovating for the future Seize the opportunity and make efforts, with grassland yogurt leading a new trend in healthy consumption Bai “slide” releases continuously: shrimp slides innovate constantly to unlock consumers' diverse needs China lotus root food industry: exploration B end and C The end is near, welcoming a new high-profit blue ocean market New snack categories are accelerating their layout, and the trend towards healthier snacks may become mainstream. Driven by both scale and branding, it leads the vigorous development of China's Fatty Beef Roll industry. Channels are king, and the Chinese tea industry has entered an era of branding Global Selection, creating a high-end quality life for children's milk The national trend is on the rise, and the healthy economy is driving the continuous development of China's fruit juice and soda industry. With innovative flavors, the black truffle milk chocolate mooncake has taken off like a golden sprinter Consumption trends are changing, and chain retail stores are ushering in a golden age for fruit consumption Food and Beverage Industry Advisory Cases (Scroll up and down for more) Frost & Sullivan assisted TEHAI International in successfully going public in the US (NASDAQ:HDL) Frost & Sullivan assisted TeaBallood in successfully going public in Hong Kong (2555.HK)   Frost & Sullivan assisted Lancang Ancient Tea in successfully listing on the Hong Kong Stock Exchange (6911.HK) Frost & Sullivan assisted Sichuan Dekang Agriculture and Animal Husbandry in successfully going public in Hong Kong (2419.HK) Frost & Sullivan assisted Kuaquan in successfully going public in Hong Kong (2517.HK) Frost & Sullivan assistance Davis Commodities Successfully listed in the US (NASDAQ: DTCK) Frost & Sullivan assisted Zhenjiao Lidu in successfully going public in Hong Kong (6979.HK) Frost & Sullivan assisted DAS Group in successfully listing on the Hong Kong Stock Exchange (1405.HK) Frost & Sullivan assisted Shenzhen Baihuagarden in successfully going public in Hong Kong (2411.HK) Frost & Sullivan assisted Zhengwei Group in successfully going public in Hong Kong (2147.HK) Frost & Sullivan assisted Weilong in successfully going public in Hong Kong (9985.HK) Frost & Sullivan assisted Shuangcaizhuang in successfully going public on the Hong Kong Stock Exchange (2321.HK) Frost & Sullivan assisted Youran Muying in successfully going public on the Hong Kong Stock Exchange (9858.HK) Frost & Sullivan assisted Joyou Wang in successfully going public in Hong Kong (1927.HK) Frost & Sullivan assisted BSWG in successfully listing on the Hong Kong Stock Exchange (9987.HK) Frost & Sullivan assisted Nongfu Spring in successfully going public on the Hong Kong Stock Exchange (9633.HK) Frost & Sullivan assisted Fengxiang Food in successfully listing on the Hong Kong Stock Exchange (9977.HK) Frost & Sullivan assisted SIMOR to successfully go public in Hong Kong (6969.HK) Frost & Sullivan assists China's Feihai in successfully going public in Hong Kong (6186.HK) Frost & Sullivan assisted China National Tobacco International in successfully going public in Hong Kong (6055.HK) Frost & Sullivan helps select top-quality products. 360 Successfully listed on the Hong Kong stock market (2360.HK) Frost & Sullivan assisted Wugu Mofang in successfully going public in Hong Kong (1837.HK) Frost & Sullivan assisted BaoBABA in successfully listing on the Hong Kong Stock Exchange (1761.HK) Frost & Sullivan assisted Haidilao in successfully listing on the Hong Kong Stock Exchange (6862.HK) Frost & Sullivan assists sustainable agriculture in successfully listing on the Hong Kong Stock Exchange (8609.HK) Frost & Sullivan assisted Longhui Holdings in successfully listing on the Hong Kong Stock Exchange (1007.HK) Frost & Sullivan assisted Xinrong International in successfully going public in Hong Kong (1587.HK) Frost & Sullivan assisted Yiyuan Liquor Industry in successfully listing on the Hong Kong Stock Exchange (8146.HK) Frost & Sullivan assisted Jierong International in successfully listing on the Hong Kong Stock Exchange (2119.HK) Frost & Sullivan assisted BNP Paribas International in successfully listing on the Hong Kong Stock Exchange (1705.HK) Frost & Sullivan assisted Nippon Sake & Foods in successfully going public in Hong Kong (1475.HK) Frost & Sullivan assists Asian grocery giant in successfully listing on the Hong Kong Stock Exchange (8413.HK) Frost & Sullivan assisted Chow Hing Duck in successfully going public in Hong Kong (1458.HK) Frost & Sullivan assisted COFCO Meat Group in successfully listing on the Hong Kong Stock Exchange (1610.HK) Frost & Sullivan assisted Yihai International in successfully going public in Hong Kong (1579.HK) Frost & Sullivan assisted Zhongdi Dairy in successfully going public in Hong Kong (1492.HK) Frost & Sullivan assisted Dahili Foods in successfully going public in Hong Kong (3799.HK) Frost & Sullivan assists Manor Ranch in successfully going public in Hong Kong (1533.HK)   Frost & Sullivan assisted Vientiane International in successfully listing on the Hong Kong Stock Exchange (0288.HK)   * The above order is not sequential and is arranged in reverse chronological order by listing time.

To recognize the value creators who have made outstanding contributions to China's healthcare industry over the past year and establish an industry benchmark of 'respecting value, embracing value, and creating value', On May 15, 2024, the "2023 China Healthcare Industry Investment and Financing Honor Roll" jointly launched by CHC Medical Consulting and CITIC Securities was officially released.   The 'Annual China Healthcare Industry Investment and Financing Honor Roll' is an authoritative third-party list in the healthcare sector, based on a comprehensive review of the current investment and financing development of the healthcare industry. It uses multiple criteria such as institutional activity, number of investment projects, outstanding cases, investment returns, total managed capital, corporate financing and development status, and valuation to select the top 15 awards across five categories: Investment Institutions, Enterprises, Services, Parks, and Individuals. The list is selected based on the principles of fairness and justice, aiming to recognize and reward the best in each category.   Since the release of the first list in 2018, the Honor Roll has become one of the important benchmarks for the development and investment financing of China's healthcare industry. The release of the Honor Roll is not only an acknowledgment and affirmation of the value contributors to the healthcare industry but also an encouragement and motivation for the entire industry, reflecting the positive values and energy within the sector.   Frost & Sullivan (Frost & Sullivan, abbreviated as "Frost & Sullivan") safeguards the development of clients with its excellent service quality, profound professional competence, and exquisite practice skills. It provides efficient and high-quality professional services for the healthcare industry and has been listed among the "Top 5 Most Trusted Healthcare Service Providers of 2023" for its outstanding team performance.   Frost & Sullivan, integrating 63 years of global consulting experience, has dedicated 26 years to serving the booming Chinese market. With a global perspective, it helps clients accelerate their business growth, achieving industry-leading benchmarks in terms of growth, innovation, and leadership. The big health industry is one of the core areas of focus for Frost & Sullivan.   Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, it has unique core advantages in investment and financing services for the life science industry. Frost & Sullivan has a wide range of corporate clients in China, having established a vast client network over the past 20 years and accumulated extensive project experience in various sub-sectors of life sciences. Project types include knowledge center projects (in-depth content, promotional activities), Pre-IPO projects (DCF valuation, business plan services), IPO listing projects (industry advisory, clinical audit, fundraising and investment writing), market research, market value management, and strategic consulting, etc. It also collaborates with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized sub-sectors such as pharmaceuticals and medical devices, attracting widespread attention from investors.   As an industry advisor, Frost & Sullivan has become the preferred partner for healthcare companies seeking to list in Hong Kong and overseas with its exceptional services. According to publicly disclosed information from the Hong Kong Exchange, from 2015 to 2023, Frost & Sullivan maintained a leading position in the Hong Kong stock market's listed advisory segment for nine consecutive years, accounting for the largest proportion of listed companies in the sector. It is an absolute leader in serving healthcare companies seeking to list in Hong Kong. In addition, since the first batch of companies on the Sci-Tech Innovation Board (STAR Market) was listed in July 2019, Frost & Sullivan reports have been widely cited in the prospectuses of leading STAR Market-listed companies, accounting for up to 75% of the market share.   Since 2018, Frost & Sullivan has continuously published multiple industry blue books in the field of life sciences, such as 'Blue Book on the Current Development and Future Trends of Medical Beauty Injection Products', 'Blue Book on the Current Situation and Future Development Trends of High-End Ophthalmic Medical Equipment', 'Blue Book on the Development of Tumor Molecular Diagnostics Industry', 'Blue Book on the Current Situation and Development Trends of Vascular Interventional Special Balloons', 'Blue Book on the Current Situation and Future Development of China's Radioactive Drug Industry', 'Blue Book on the Current Situation and Development Trends of Gene Drugs Industry', 'Blue Book on the Development of Hong Kong's 18A & Sci-Tech Innovation Board Biotechnology Industry in 2023', etc. These books deeply analyze the current development status and future trends of various sub-industries, providing valuable reference perspectives for market investors.   In the future, Frost & Sullivan will continue to increase its investment and focus on the life sciences field, actively explore new service and business models, pay attention to policy changes and market demands in this area, and provide clients with more professional and efficient consulting services. We hope to work with more healthcare enterprises to understand industry trends, seize development opportunities, jointly promote the prosperity and development of China's healthcare industry, and contribute to the cause of human health.   Recent Life Sciences Industry Advisory Cases (Scroll Up and Down for More) Frost & Sullivan assists Tsuen Shin Bio to successfully go public in Hong Kong (2509.HK) Frost & Sullivan assists Meizhong Jiahé in successfully listing on the Hong Kong Stock Exchange (2453.HK) Frost & Sullivan helps WuXi AppTec Biologics (0138.HK) successfully go public in Hong Kong Frost & Sullivan assisted Hangzhou Anuo Medicine in successfully going public on NASDAQ (NASDAQ:ANL) Frost & Sullivan Eastsoft in listed(9686.HK) Frost & Sullivan assisted Yuzhiyou in successfully going public in Hong Kong (2496.HK) Frost & Sullivan helps Yiming Angke successfully go public in Hong Kong (1541.HK) Frost & Sullivan assists ColomboTEC in successfully listing on the Hong Kong Stock Exchange (6990.HK) Frost & Sullivan assists LaiKai Medicine in successfully listing on the Hong Kong Stock Exchange (2105.HK) Frost & Sullivan assists Keddy Group in successfully listing on the Hong Kong Stock Exchange (2487.HK) Frost & Sullivan assists Lüzhoubio in successfully listing on the Hong Kong Stock Exchange (2480.HK) Frost & Sullivan helps MesHealth successfully go public in Hong Kong (2415.HK) Frost & Sullivan assisted Yihua Pharmaceutical in successfully issuing GDRs and listing on the Luxembourg Stock Exchange (PHECR). Frost & Sullivan assists Zhongjin Medical in successfully going public in the US (NASDAQ: ZJYL) Frost & Sullivan assisted Yisheng Biology in successfully going public in the US (NASDAQ:YS) Frost & Sullivan assists Meiliyuan in successfully listing on the Hong Kong Stock Exchange (2373.HK) Frost & Sullivan assists Kangfeng Biotech in successfully listing on the Hong Kong Stock Exchange (6922.HK) Frost & Sullivan assists Bo'an Biosciences in successfully listing on the Hong Kong Stock Exchange (6955.HK) Frost & Sullivan helps Thundersoft successfully go public in Hong Kong (1244.HK) Frost & Sullivan assists Meihao Medical in successfully listing on the Hong Kong Stock Exchange (1947.HK) Frost & Sullivan assists Gaowei Medical in successfully listing on the Hong Kong Stock Exchange (2407.HK) Frost & Sullivan helps Lepuventec successfully go public in Hong Kong (2291.HK) Frost & Sullivan assisted Genvid Biotech in successfully listing on the Hong Kong Stock Exchange (9877.HK) Frost & Sullivan assisted Health Yuan in successfully issuing GDRs and listing on the Ruixin Stock Exchange (JCARE.SW) Frost & Sullivan assisted Lepu Medical in successfully issuing GDRs and listing on the Ruixin Stock Exchange (LEPU.SW) Frost & Sullivan assists Dingdang Health in successfully listing on the Hong Kong Stock Exchange (9886.HK) Frost & Sullivan helps Bio-TheraPlex successfully list on the Hong Kong Stock Exchange (2315.HK) Frost & Sullivan helps Zhiyun Health successfully go public in Hong Kong (9955.HK) Frost & Sullivan assists MeinGene in successfully listing on the Hong Kong Stock Exchange (6667.HK) Frost & Sullivan assists Prenetics in successfully going public on the NASDAQ (NASDAQ:PRE) Frost & Sullivan assists YunKang Group in successfully listing on the Hong Kong Stock Exchange (2325.HK) Frost & Sullivan assisted Ruike Biotech in successfully listing on the Hong Kong Stock Exchange (2179.HK) Frost & Sullivan assisted Lepu Biosciences in successfully listing on the Hong Kong Stock Exchange (2157.HK) Frost & Sullivan helps Clear Medical successfully go public in Hong Kong (1406.HK) Frost & Sullivan assists Centric Software Group Limited (0638.HK) in successfully listing on the Hong Kong Stock Exchange (2185.HK) Frost & Sullivan assists Yonghe Medical in successfully listing on the Hong Kong Stock Exchange (2279.HK) Frost & Sullivan assists Kaleido in successfully listing on the Hong Kong Stock Exchange (6821.HK) Frost & Sullivan assists North China Cosmopolitan Pharmaceutical Group Limited (0673.HK) in successfully going public in Hong Kong (1228.HK) Frost & Sullivan helps Gushengtang successfully go public in Hong Kong (2273.HK) Frost & Sullivan assists Yingpeng Technology in successfully listing on the Hong Kong Stock Exchange (2251.HK) Frost & Sullivan helps Clover Biotechnology successfully list on the Hong Kong Stock Exchange (2197.HK) Frost & Sullivan helps minimally invasive robotics successfully list on the Hong Kong Stock Exchange (2252.HK) Frost & Sullivan assisted Yuhuan in successfully listing on the Hong Kong Stock Exchange (2256.HK) Frost & Sullivan assists Kunbo Medical in successfully going public in Hong Kong (2216.HK) Frost & Sullivan assisted Xianruida in successfully listing on the Hong Kong Stock Exchange (6669.HK) Frost & Sullivan assists Conserve Global in successfully listing on the Hong Kong Stock Exchange (9960.HK) Frost & Sullivan assists Tengsheng Bio-Tech Group in successfully listing on the Hong Kong Stock Exchange (2137.HK) Frost & Sullivan assists Conocoalt in successfully listing on the Hong Kong Stock Exchange (2162.HK) Frost & Sullivan assists Chaoyu Eye Hospital in successfully listing on the Hong Kong Stock Exchange (2219.HK) Frost & Sullivan helps Guichuangtongqiao successfully go public on the Hong Kong Stock Exchange (2190.HK) Frost & Sullivan assisted Hualong Medicine in successfully listing on the Hong Kong Stock Exchange (0013.HK) Frost & Sullivan assists Celyion Pharmaceuticals in successfully listing on the Hong Kong Stock Exchange (2171.HK) Frost & Sullivan assists Megvii Ophthalmics in successfully listing on the Hong Kong Stock Exchange (6622.HK) Frost & Sullivan assists Nature Pharma in successfully going public in the US (NASDAQ) : UPC) Frost & Sullivan assists Sino Biologics Group Limited (6600.HK) in successfully listing on the Hong Kong Stock Exchange Frost & Sullivan assists Zhaoyan New Drugs in successfully listing on the Hong Kong Stock Exchange (6127.HK) Frost & Sullivan assists Novo Nordisk Health in successfully listing on the Hong Kong Stock Exchange (6606.HK) Frost & Sullivan assisted Tianyan Pharmaceutical in successfully going public in the US (NASDAQ: ADAG) Frost & Sullivan assists BeiGene Healthcare in successfully listing on the Hong Kong Stock Exchange (2170.HK) Frost & Sullivan helps Jianbaimiao Miao successfully go public in Hong Kong (2161.HK) Frost & Sullivan helps Minimally Invasive Cardiac Therapy (MICT) successfully go public in Hong Kong (2160.HK) Frost & Sullivan assists RuiLi Medical Beauty in successfully listing on the Hong Kong Stock Exchange (2135.HK) Frost & Sullivan assists Gaoke Pharmaceutical in successfully listing on the Hong Kong Stock Exchange (1167.HK) Frost & Sullivan facilitated the successful listing of BeiGene Pharma on the Hong Kong Stock Exchange (2142.HK) Frost & Sullivan helps JD Health successfully go public in Hong Kong (6618.HK) Frost & Sullivan assists Deqi Medicine in successfully listing on the Hong Kong Stock Exchange (6996.HK) Frost & Sullivan assists Rongchang Biology in successfully listing on the Hong Kong Stock Exchange (9995.HK) Frost & Sullivan assists WuXi AppTec Biologics (HKG 2126) in successfully listing on the Hong Kong Stock Exchange Frost & Sullivan assists SinoPharma Biologics Limited on its successful listing on the Hong Kong Stock Exchange (2096.HK) Frost & Sullivan assisted Yuntop New Energy in successfully listing on the Hong Kong Stock Exchange (1952.HK) Frost & Sullivan assists Jiahé Biotech in successfully listing on the Hong Kong Stock Exchange (6998.HK) Frost & Sullivan assisted Zai Lab Biologics on its successful listing on the Hong Kong Stock Exchange (9688.HK) Frost & Sullivan assists OcularVista in successfully listing on the Hong Kong Stock Exchange (1477.HK) Frost & Sullivan assists Yongtai Biotech in successfully listing on the Hong Kong Stock Exchange (6978.HK) Frost & Sullivan assists Hype Pharma in successfully listing on the Hong Kong Stock Exchange (9989.HK) Frost & Sullivan helps develop PharmaCure successfully go public in Hong Kong (9939.HK) Frost & Sullivan assisted Peijia Medical in successfully listing on the Hong Kong Stock Exchange (9996.HK) Frost & Sullivan assisted Kangfang Biotech in successfully listing on the Hong Kong Stock Exchange (9926.HK) Frost & Sullivan assists Nuo Cheng Jianhua in successfully listing on the Hong Kong Stock Exchange (9969.HK) Frost & Sullivan assisted Tianjing BIO in successfully going public on NASDAQ (NASDAQ:IMAB) Frost & Sullivan assists Conchaime Pharma in successfully listing on the Hong Kong Stock Exchange (3759.HK) Frost & Sullivan assists China's antibody company in successfully listing on the Hong Kong Stock Exchange (3681.HK) Frost & Sullivan assists Dongyao Pharmaceutical in successfully listing on the Hong Kong Stock Exchange (1875.HK) Frost & Sullivan assists Yasheng Medicine in successfully listing on the Hong Kong Stock Exchange (6855.HK) Frost & Sullivan helps Fosun Pharma successfully go public in Hong Kong (2696.HK) Frost & Sullivan assisted Hansen Pharma in successfully listing on the Hong Kong Stock Exchange (3692.HK) Frost & Sullivan assists Mybiopharmaceuticals in successfully listing on the Hong Kong Stock Exchange (2181.HK) Frost & Sullivan assisted Fangda Holdings in successfully listing on the Hong Kong Stock Exchange (1521.HK) Frost & Sullivan assists ViaBio in successfully listing on the Hong Kong Stock Exchange (1873.HK) Frost & Sullivan helps Cornerstone Pharmaceuticals successfully go public in Hong Kong (2616.HK) Frost & Sullivan assists Junshi Biosciences in successfully listing on the Hong Kong Stock Exchange (1877.HK) Frost & Sullivan helps WuXi AppTec successfully go public in Hong Kong (2359.HK) Frost & Sullivan assisted Innovent Biologics in successfully listing on the Hong Kong Stock Exchange (1801.HK) Frost & Sullivan assists Hualing Medicine in successfully listing on the Hong Kong Stock Exchange (2552.HK) Frost & Sullivan helps BeiGene successfully go public in Hong Kong (6160.HK) Frost & Sullivan assists GlaxoSmithKline Pharmaceutical Group Limited (01672.HK) in successfully listing on the Hong Kong Stock Exchange Frost & Sullivan helps WuXi AppTec Biologics successfully go public in Hong Kong (2269.HK) Frost & Sullivan assists China Resources Pharmaceutical in successfully listing on the Hong Kong Stock Exchange (3320.HK) Frost & Sullivan assists Jacobson Scientific & Pharmaceutical Group in successfully listing on the Hong Kong Stock Exchange (2633.HK) Frost & Sullivan assisted Hua Huang China Medicine in successfully going public on NASDAQ (HCM) Frost & Sullivan assists KingsRice Biotechnology in successfully listing on the Hong Kong Stock Exchange (1548.HK) Frost & Sullivan assists BBI Life Sciences in successfully listing on the Hong Kong Stock Exchange (1035.HK) *The above order is not sequential and is arranged in reverse chronological order based on listing time.

Frontiers Innovation Forum on Peptide and Nucleic Acid Drugs 2024 year 5 month 10 - 11 Date, hosted by Pharmaceutical Knowledge PNT The Frontier Innovation Forum on Peptide and Nucleic Acid Drugs was successfully held in Shanghai. This conference focused on peptides, small nucleic acids, mRNA Hot topics related to drug research and development, process development, quality research, commercial production, etc., are covered by four special forums. Invitations are extended to 60+ Experts, scholars, research backbones, and enterprise representatives from related fields across the country exchanged experiences to jointly discuss the future development of peptide and nucleic acid drugs.   Frost & Sullivan Frost & Sullivan Li Qian, consulting director of the Life Sciences Business Unit in Greater China at Frost & Sullivan, was invited to attend the event and delivered a presentation on mRNA Delivered a speech on "The Current Situation and Trends of the Pharmaceutical Market". Consulting Director, Life Sciences Business Unit, Frost & Sullivan Greater China Region Li Qian Li Qian pointed out that looking back at the exploration of disease treatment, people have never stopped pursuing higher safety and better patient outcomes. mRNA Drug research and development is highly efficient, with a simple production process and the ability to expand into diverse disease areas. It represents a highly promising innovative therapy and is a current research hotspot in the biopharmaceutical industry. As of now, there are 8 model mRNA Vaccine approved for marketing, domestic manufacturers mRNA Vaccines have also made significant progress. Driven by factors such as breakthroughs in key technologies, commercial success, multi-party R&D cooperation, and policy support, the future mRNA The pharmaceutical market has tremendous potential. Source: Analysis by Frost & Sullivan According to a study by Frost & Sullivan, as of 2024 year 1 months, globally 162 model mRNA The drug is in the clinical stage, mainly comprising mRNA Vaccines, accounting for approximately 70% , and most mRNA The drug is still in I period and II Phase clinical stage. In terms of therapeutic areas, global clinical research is ongoing mRNA The main indications for the drug pipeline are infectious diseases and tumors, accounting for more than half of all pipelines. 90% Currently, the indications with relatively rapid progress include melanoma, non-small cell lung cancer, colorectal cancer, and head and neck cancer. In addition, glioma, pancreatic cancer, and gynecological tumors are also included. mRNA Drug research and development.   Li Qian said, mRNA The drug production process is simple and fast, and the upstream and downstream industries of the supply chain are becoming increasingly mature. In the future, as the R&D system is gradually improved and technological applications mature, mRNA The pharmaceutical market in the therapeutic field will continue to expand, with the industry achieving synchronous development and realizing commercial cooperation.     More exciting moments from the event arena About Frost & Sullivan's Life Sciences Practice The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life sciences industry. The Life Sciences Practice has a wide range of corporate clients in China and in the past 20 In the year, a vast customer network was established, accumulating a wealth of project experience in various subfields of life sciences. Project types include Knowledge Center projects (in-depth content, promotional activities). Pre-IPO financing project DCF model Valuation, Business Plan Services), IPO listing We provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized sub-sectors such as pharmaceuticals and medical devices. Our services have received wide attention from investors.

  Medical devices are AI One of the important areas of application, with innovative products emerging continuously. From the perspective of the medical device industry, currently AI+ What are the key directions of investment in medical product research and development? Where does the R&D funding mainly come from? What is the return on investment? Looking at specific sub-sectors, which areas are experiencing fierce competition, and which ones are relatively blue oceans? AI In the field of medical devices, practical applications are gradually shifting from scenario exploration to commercialization transformation. How do you view this? AI What are the current dilemmas of high R&D investment in medical products and difficulties in commercialization? What are the solutions for the future? 2020 First medical record of the year AI Three types of certificates start, AI The supervision of medical equipment is constantly developing. In the future, where else do we need to further improve it?     Frost & Sullivan Frost & Sullivan Xu Chao, project manager of the Life Sciences Business Unit of Frost & Sullivan Greater China, was interviewed by China Securities Journal to discuss the “ AI+ Medical & rdquo; industry development.   China Securities Journal   * Click at the end of the article Read the original text View the full report     Q :    From the perspective of the medical device industry, currently AI+ What are the key directions of investment in medical product research and development? Where does the R&D funding mainly come from? What is the return on investment? Looking at specific sub-sectors, which areas have fierce competition and which ones are relatively blue oceans? Currently, clinical needs are developing towards precision, minimally invasive techniques, intelligence, and remoteization. Consequently, medical devices and AI The integration of technologies is also becoming increasingly close-knit, AI Technology has been widely applied in various sub-sectors of medical devices. AI+ The investment focus on medical product research and development is mainly concentrated in auxiliary diagnosis and imaging recognition, intelligent medical devices, personalized medicine, etc. Driven by the increasing maturity of technology and the improvement of policy systems, medical devices AI The application of the track is gradually moving from the initial development stage to a deeper implementation phase. At the same time, rapid development cannot be separated from the continuous attention and vitality injected into the medical device sector by primary or secondary markets. 2021 In [year], Eagle Vision Technology made a splash at the Hong Kong Stock Exchange, becoming a healthcare AI The first stock listed. Looking at the sub-sectors, AI Medical imaging has become a popular application area in recent years. Pulmonary nodules and fundus screening are two disease areas that companies are widely deploying in at present. In addition, the era of robotics is subverting various traditional surgeries and presenting trends such as informatization, intelligence, and minimally invasive techniques. AI The surgical robot industry is also developing rapidly. Currently, the main technical bottlenecks are insufficient data volume and algorithmic interpretability, which affect the promotion scope and application effectiveness of artificial intelligence in the medical device industry. Products and related enterprises that can break through these bottlenecks in the future will bring new development momentum to the industry.     Q :    AI In the field of medical devices, practical applications are gradually shifting from scenario exploration to commercialization. What's your view? AI What are the current dilemmas of high R&D investment in medical products and difficulties in commercialization? What solutions do you think there are for the future? AI The practical application in the field of medical devices is shifting from scenario exploration to commercialization, which is a positive trend that demonstrates its market potential and practical value. However, at present AI Medical products indeed face the dilemma of high R&D investment and difficult commercialization, mainly due to various factors such as technological maturity, business model, and regulatory policies. Firstly, from the perspective of business model, AI The research, development, and commercialization of medical products require the construction of a complete industrial chain, including upstream data collection, processing, and analysis, midstream algorithm model development and optimization, as well as downstream medical service provision and market promotion. In this process, each link needs to cooperate closely to form an effective business model. Secondly, technological breakthroughs are also key to solving the challenges of commercialization. Currently, AI Medical products need further improvement in terms of algorithm accuracy, stability, and reliability. In addition, data security and privacy protection are also AI An important consideration in the development of medical technology. Strengthen research and application of data governance and privacy protection technologies to ensure the security and compliance of patient data. Furthermore, regulatory policies also have an impact AI An important factor in the commercialization and implementation of medical products. With AI With the rapid development of technology, regulatory authorities need to formulate and improve corresponding laws, regulations, standards, and norms to AI The commercialization of medical products provides strong institutional support.     Q :    from 2020 First medical record of the year AI Three types of certificates start, AI The supervision of medical equipment is constantly developing. In the future, where else do we need to further improve it? since 2020 year 1 In the month, Keya Medical obtained Class III medical device certification, marking China AI Medical devices have entered the commercialization stage. As regulatory pathways become increasingly clear, the number of approvals for Class III certificates will increase. As of 2023 year 6 month 30 day, already 63 The product has successfully obtained Class 3 certificates. More and more III The approval of the class certificate also means that the industry's focus is shifting from research and development to commercial implementation. In recent years AI The regulatory mechanism for medical devices has made remarkable progress, but there is still room for continuous improvement in several areas. For instance, classification management and risk grading strategies can be implemented to clarify the scope of use and limitations for different types of large models. 2022 The "Guiding Principles for the Registration and Review of Artificial Intelligence Medical Devices" (hereinafter referred to as the "Principles") promulgated in [year] AI The specific positioning and uses of medical device products have been carefully divided and supplemented with explanations, providing clear guidance for supervision. In terms of data sources, the 'Principles' detail three types of data sources, all of which share the common characteristic of being objective data used for medical purposes. To ensure the accuracy and reliability of data, it is necessary to strengthen the review of training data sources and quality, clarify compliance requirements for data collection and use, thereby effectively preventing data abuse and privacy leaks. In addition, an accountability system for medical large models can be explored to ensure clear and traceable responsibilities. Through the implementation of these measures, we will be able to further improve. AI The regulatory mechanism for medical devices ensures their safety and effective service to public health.   * This interview has been published in 'China Securities Journal', with reporter Li Mengyang and the original title being '    " AI+ Medical ”Rising Tides Medical device companies explore commercial models    >>

In recent years, the baking industry has seen an accelerated reshuffle of brands. Brands such as "Panda Does Not Leave," "Tiger Head Bureau," and "Mo Mo's Pastries Bureau" have gone from rapid expansion to desperate survival in just a few years, with some even closing down. How do we view this phenomenon? What role has capital played in it? What is the connection between the entry of capital and the accelerated reshuffle of the industry? What are the advantages and disadvantages of capital entry? At the same time, some baking brands have established themselves through different marketing strategies. What are the differences in their marketing strategy directions? Why can they stand firm in the baking industry? What are your views on the future of the baking industry? Which type of bakery can continue to survive and develop? How should bakery stores respond to today's economic and consumption patterns?     Frost & Sullivan Frost & Sullivan Lou Lei, Executive Director of Frost & Sullivan's Greater China Region (hereinafter referred to as 'Frost & Sullivan'), was interviewed by CCTV Finance Channel, sharing his observations on the baking market.   CCTV Finance   * Click at the end of the article Read the original text View the full report     Q :    In recent years, the baking industry has seen a rapid reshuffle of brands, with names such as 'Panda No Go', 'Tiger Head Bureau', and 'Mo Mo Dimsum Bureau' experiencing a shift from rapid expansion to desperate survival in just a few years, with some even going bankrupt. How do you view this phenomenon? Behind this phenomenon is the result of multiple factors interacting with each other, which includes not only changes in the external environment but also reveals deficiencies in brand internal management. Why can it expand rapidly in a short period of time: 1 Brand rejuvenation and precise positioning: These are typical new consumer brands that have not been around for long, but have quickly gained the favor of young consumers with their youthful brand image and precise product positioning. For example, Hooters' macaroni tiger rolls and Panda's door-to-door service stand out in the market with their unique selling points. 2 Online and offline integration with internet traffic strategies: New consumer brands deeply understand the art of internet traffic, utilizing an integrated online and offline business model to fully leverage social media, short videos, and other internet tools for rapid brand dissemination and sales growth. 3 Explosive expansion fueled by capital: In addition, 2020 Year-end 2022 Against the backdrop of a new wave of consumer investment in recent years, a large number of new consumer brands have gained the favor of capital. The resolution of funding issues has enabled these brands to achieve explosive expansion in a short period. Why have we now reached a situation where we are left with no way out: 1 The consumer environment has returned to rationality: As the market matures, consumers are making more rational choices about products and no longer blindly pursue popular online influencers and best-selling products. The baking market has also shown a trend towards returning to value for money, putting some high-priced and low-consumption frequency online influencer baked products under market pressure. 2 The return of capital to rationality and the cooling of investment enthusiasm: As the capital market's enthusiasm for large consumer investments gradually wanes, brands find it increasingly difficult to obtain substantial capital support, their expansion speed slows down, and they even face the risk of capital chain breakage. 3 Insufficient enterprise management and team capabilities: Due to their short establishment time, these brands are not yet mature in talent cultivation and management systems, leading to problems such as management chaos and unstable teams during rapid expansion. 4 Over-reliance on traffic and marketing: Brands that overly depend on traffic and marketing methods develop their business too much based on external factors. Once the market environment changes, it becomes difficult for brands to cope. At the same time, excessive marketing can also have a negative impact on brand reputation and profits. 5 There are significant weaknesses in the business model: Some brands have flaws in their business models, such as over-reliance on online food delivery platform traffic. Once platform policies change or competition intensifies, it becomes difficult for brands to maintain their market position. In summary, the phenomenon of brand reshuffling in the baking industry is an inevitable result of market development. The baking industry has broad prospects, and for new consumer brands, to stand firm in the fierce market competition, they need to examine their internal models and balance development speed with quality. In the future, brands should continue to innovate, improve product quality, and focus on consumer experience to achieve sustainable development.     Q :    What role has capital played in this? What is the connection between capital entry and the accelerated reshuffling of industries? What are the advantages and disadvantages of capital entry? In the process of brand reshuffle in the baking industry, capital has played a crucial role. Take Hutouju as an example; it gained control within a short period of time, including IDG Multiple rounds of financing, including Sequoia Capital and Challenger Capital, have rapidly driven the valuation upwards. 20 Hundreds of millions. The injection of these capitals has provided a strong financial backing for emerging brands, promoted rapid brand expansion, and quickly established a powerful brand influence in the market. However, the entry of capital has also brought about a double-edged sword effect. On one hand, capital provides valuable resources for brands, helping them quickly occupy markets and enhance brand power; on the other hand, capital also sets higher demands on brands, especially in terms of business models and operational management. This high-pressure test forces brands to deal with challenges in supply chain management, store staff management, new product development, market expansion, and other aspects within a short period. If the brand's management team is not fully prepared and able to cope with these challenges, rapid capital investment may instead become a burden on the brand. Once a balance cannot be found between quality and scale, the brand may expose its weaknesses due to rapid expansion, and even lead to a backlash against brand value. Therefore, when facing capital entry, brands should not only see the opportunities brought by capital but also be vigilant about the challenges it poses. Only by focusing on internal strength cultivation and improving management levels and operational efficiency can brands remain invincible in the fierce market competition.     Q :    At the same time, there are also some baking brands that have established themselves through different marketing strategies. Can you briefly discuss the differences in marketing strategy directions among these brands? Why are they able to stand firm in the baking industry? The current domestic baking market shows a diversified positioning and development direction, with three strategies particularly prominent: affordable, high-end, and online celebrity brands. Although these strategies are different, they each successfully found their footing in the market. Affordable brands: Such brands focus on cost-effectiveness and healthy, stable quality as their core competitiveness. They differentiate themselves from time-limited products by offering affordable and reliable products, mainly competing in markets such as supermarkets, snacks, and school meals. The essence of this strategy lies in meeting consumers' basic needs for daily consumption and winning market reputation with sustained and stable quality. High-end brands: High-end baking brands are committed to creating an image of imported, professional, and masterpieces. By emphasizing the uniqueness and high quality of their products, they adopt a similar competitive strategy with high-end dining venues such as Western restaurants. The success of this strategy lies in meeting consumers' pursuit of a high-quality life and consolidating their market position by strengthening positioning. Internet celebrity brand: Online celebrity baking brands have become a hot topic in the consumer goods industry in recent years. They have rapidly attracted a large amount of attention through innovative marketing strategies and have become hot topics on social media. However, online celebrity brands also face the dual-edged sword effect. Before becoming an online celebrity, brands usually aim at becoming internet celebrities and focus on marketing. But once they become online celebrities, how to get rid of the online celebrity label and achieve sustainable development becomes an important challenge for brands. For online celebrity brands, marketing is undoubtedly the key to breaking through the market. However, relying solely on marketing is not enough to support the long-term development of a brand. After becoming an online celebrity, the brand needs to ensure that its products themselves are competitive enough to withstand the scrutiny of consumers and the market. At the same time, the brand also needs to find a balance between popularity and development speed, maintaining market attention while controlling expansion rates to ensure profitability and brand image stability. In summary, whether it is an affordable, high-end, or internet-famous baking brand, the key to their success in the market lies in accurately identifying their positioning and formulating appropriate marketing strategies around that. At the same time, brands also need to continuously enhance their own strength to ensure the sustained competitiveness of their products, services, and brand image.     Q :    What are your views on the future of the baking industry? Which type of bakery can continue to survive and develop? How should bakeries respond to today's economic and consumption trends? According to Frost & Sullivan's calculations, the baking industry has more than 2,000 The market scale is hundreds of millions, with an average annual growth rate approaching 10% Its potential cannot be ignored. However, the highly decentralized, regionalized, and segmented characteristics of the market also bring unique challenges and opportunities to the baking industry. Looking at the benchmark enterprises in the current market, whether they are time-honored brands such as Daoxiangcun, Xinghualu, and Juxiangyuan, regional brands like Haolilai and Xingfu Western Biscuits, or imported foreign brands like Brioche and Paris Baguette, each has carved out a niche in the market with its unique competitive strategies and target customer groups. These successful cases demonstrate that different types of baking enterprises can survive and develop in different ways. For the future development direction of bakeries, there are several suggestions: 1 Steadfast progress: In a highly competitive market, maintaining a steady development pace is crucial. By continuously optimizing products and services, enhancing brand reputation, attracting and retaining consumers. At the same time, paying attention to market dynamics and changes in consumer needs, flexibly adjusting business strategies. 2 Actively embrace young consumers: Young consumers are an important consumer group in the baking market. Brands need to learn and adapt to the preferences and habits of the new generation, using new media channels such as social media and short videos for marketing and promotion. At the same time, pay attention to fashion trends and innovations, continuously developing products and services to meet the personalized needs of young consumers. 3 Adhere to the original intention of the product: While pursuing innovation and fashion, brands must not neglect the essence of their products. High-quality products are the foundation for a brand to stand firm in the market. Brands need to always adhere to the original intention of their products, continuously improve product quality and taste, and win the trust and loyalty of consumers. In addition, when facing today's economic and consumption trends, bakeries should also pay attention to the following points: 1 Cost Control: Against the backdrop of fluctuating raw material prices and rising labor costs, brands need to strengthen cost control and improve operational efficiency. By optimizing supply chain management and reducing inventory costs, they can lower costs and enhance profitability. 2 Digital Transformation: Utilize advanced technologies such as big data and artificial intelligence for digital transformation to improve brand operational efficiency and consumer experience. For instance, understand consumer needs and market trends through data analysis to formulate more precise marketing strategies; improve production efficiency and product quality through smart devices, etc. 3 Sustainable Development: With the increasing awareness of environmental protection, brands need to pay attention to sustainable development issues. Measures such as using environmentally friendly materials and packaging, and promoting green production methods can help enhance brand image and consumer loyalty. In summary, the baking industry will continue to maintain a decentralized, stratified, and diverse competitive landscape in the future. Brands need to develop appropriate competitive strategies and development directions based on their own characteristics and market demands, while also paying attention to issues such as cost control, digital transformation, and sustainable development to achieve long-term stable development. * This interview has been broadcast on CCTV Finance Channel. The reporter is Wang Yannan, and the original title was 'Observations on the Baking Market'. "Panda doesn't leave" cake store closes down on a large scale Baking Track Accelerated Rebranding', 'Baking Market Observation' Meet consumers' diversified needs Baking merchants adjust strategies to stay ahead of the curve